Barclays PLC Alnylam Pharmaceuticals, Inc. Call Options Transaction History

Barclays PLC

$377 Billion
Q3 2024

Call Options

19 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 15, 2024	SELL	$233.81 - $287.01 $14.1 Million - $17.3 Million	-60,400 Reduced 75.97%	19,100 $5.25 Million
Q2 2024 Aug 14, 2024	BUY	$143.31 - $247.0 $7.28 Million - $12.5 Million	50,800 Added 177.0%	79,500 $19.3 Million
Q1 2024 May 15, 2024	SELL	$146.51 - $198.2 $2.3 Million - $3.11 Million	-15,700 Reduced 35.36%	28,700 $4.29 Million
Q4 2023 Feb 15, 2024	BUY	$151.41 - $196.57 $6.72 Million - $8.73 Million	44,400 New	44,400 $8.5 Million
Q1 2023 May 04, 2023	SELL	$182.66 - $235.53 $5.13 Million - $6.62 Million	-28,100 Reduced 38.23%	45,400 $9.09 Million
Q4 2022 Feb 13, 2023	BUY	$185.53 - $241.31 $13.6 Million - $17.7 Million	73,500 New	73,500 $17.5 Million
Q2 2021 Aug 13, 2021	BUY	$128.63 - $176.89 $3.78 Million - $5.2 Million	29,400 Added 4900.0%	30,000 $5.09 Million
Q2 2020 Aug 12, 2020	SELL	$104.21 - $156.44 $4.39 Million - $6.59 Million	-42,100 Reduced 98.59%	600 $89,000
Q1 2020 May 13, 2020	SELL	$93.12 - $133.99 $2.69 Million - $3.87 Million	-28,900 Reduced 40.36%	42,700 $4.65 Million
Q4 2019 Feb 10, 2020	BUY	$74.51 - $124.23 $3.79 Million - $6.31 Million	50,800 Added 244.23%	71,600 $8.25 Million
Q3 2019 Nov 14, 2019	BUY	$70.9 - $87.82 $496,300 - $614,740	7,000 Added 50.72%	20,800 $1.67 Million
Q2 2019 Aug 14, 2019	SELL	$65.86 - $92.79 $105,376 - $148,464	-1,600 Reduced 10.39%	13,800 $1 Million
Q1 2019 May 15, 2019	SELL	$72.76 - $93.45 $1.59 Million - $2.04 Million	-21,800 Reduced 58.6%	15,400 $1.44 Million
Q4 2018 Feb 14, 2019	SELL	$62.67 - $88.33 $908,715 - $1.28 Million	-14,500 Reduced 28.05%	37,200 $2.71 Million
Q3 2018 Nov 14, 2018	SELL	$87.52 - $122.67 $1.3 Million - $1.83 Million	-14,900 Reduced 22.37%	51,700 $4.52 Million
Q2 2018 Aug 14, 2018	BUY	$88.31 - $107.8 $150,127 - $183,260	1,700 Added 2.62%	66,600 $6.56 Million
Q1 2018 May 15, 2018	SELL	$115.92 - $148.54 $1.87 Million - $2.39 Million	-16,100 Reduced 19.88%	64,900 $7.73 Million
Q4 2017 Feb 14, 2018	SELL	$114.49 - $139.98 $19.9 Million - $24.3 Million	-173,800 Reduced 68.21%	81,000 $10.3 Million
Q3 2017 Nov 14, 2017	BUY	$72.53 - $118.27 $18.5 Million - $30.1 Million	254,800	254,800 $29.9 Million

Others Institutions Holding ALNY

# of Institutions

644

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

Capital World Investors Los Angeles, CA

16.5M
Shares

$4.18 Billion
0.73% of portfolio
Vanguard Group Inc Valley Forge, PA

12.6M
Shares

$3.2 Billion
0.06% of portfolio
Black Rock Inc. New York, NY

9.55M
Shares

$2.42 Billion
0.05% of portfolio
Capital Research Global Investors Los Angeles, CA

5.24M
Shares

$1.33 Billion
0.31% of portfolio
Wellington Management Group LLP Boston, MA

4.95M
Shares

$1.25 Billion
0.24% of portfolio

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account